Compare ASTRAZENECA PHARMA with Fulford India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs FULFORD INDIA - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

FULFORD INDIA 
   Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA FULFORD INDIA ASTRAZENECA PHARMA/
FULFORD INDIA
 
P/E (TTM) x 114.6 398.8 28.7% View Chart
P/BV x 33.5 6.2 539.3% View Chart
Dividend Yield % 0.0 0.1 -  

Financials

 ASTRAZENECA PHARMA   FULFORD INDIA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
FULFORD INDIA
Mar-14
ASTRAZENECA PHARMA/
FULFORD INDIA
5-Yr Chart
Click to enlarge
High Rs1,278942 135.7%   
Low Rs883450 196.1%   
Sales per share (Unadj.) Rs228.4691.4 33.0%  
Earnings per share (Unadj.) Rs10.411.5 90.4%  
Cash flow per share (Unadj.) Rs16.315.4 105.9%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.3 0.0%  
Book value per share (Unadj.) Rs98.8380.0 26.0%  
Shares outstanding (eoy) m25.003.90 641.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.71.0 469.8%   
Avg P/E ratio x104.260.7 171.7%  
P/CF ratio (eoy) x66.445.3 146.6%  
Price / Book Value ratio x10.91.8 597.2%  
Dividend payout %017.4 0.0%   
Avg Mkt Cap Rs m27,0082,714 995.0%   
No. of employees `0001.40.4 305.4%   
Total wages/salary Rs m1,535505 304.0%   
Avg. sales/employee Rs Th4,210.96,073.0 69.3%   
Avg. wages/employee Rs Th1,132.21,137.4 99.5%   
Avg. net profit/employee Rs Th191.1100.7 189.8%   
INCOME DATA
Net Sales Rs m5,7102,696 211.8%  
Other income Rs m123125 97.7%   
Total revenues Rs m5,8332,822 206.7%   
Gross profit Rs m463-46 -997.6%  
Depreciation Rs m14715 969.7%   
Interest Rs m010 0.0%   
Profit before tax Rs m43854 806.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m17910 1,863.5%   
Profit after tax Rs m25945 579.6%  
Gross profit margin %8.1-1.7 -471.1%  
Effective tax rate %40.817.7 231.0%   
Net profit margin %4.51.7 273.7%  
BALANCE SHEET DATA
Current assets Rs m3,2091,738 184.6%   
Current liabilities Rs m2,070545 379.9%   
Net working cap to sales %20.044.3 45.1%  
Current ratio x1.63.2 48.6%  
Inventory Days Days7248 149.3%  
Debtors Days Days354 811.2%  
Net fixed assets Rs m79012 6,641.2%   
Share capital Rs m5039 128.2%   
"Free" reserves Rs m2,4191,443 167.7%   
Net worth Rs m2,4691,482 166.6%   
Long term debt Rs m00-   
Total assets Rs m4,6052,077 221.8%  
Interest coverage xNM6.7-  
Debt to equity ratio x00-  
Sales to assets ratio x1.21.3 95.5%   
Return on assets %5.62.6 215.6%  
Return on equity %10.53.0 347.9%  
Return on capital %17.74.3 412.0%  
Exports to sales %00-   
Imports to sales %024.5 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA659 0.0%   
Fx inflow Rs m30017 1,741.6%   
Fx outflow Rs m2,015673 299.3%   
Net fx Rs m-1,715-656 261.5%   
CASH FLOW
From Operations Rs m8890 97.7%  
From Investments Rs m-94105 -89.5%  
From Financial Activity Rs mNA-14 0.0%  
Net Cashflow Rs m-6181 -3.2%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 75.0 100.0%  
Indian inst/Mut Fund % 0.3 3.8 7.9%  
FIIs % 15.7 0.1 15,700.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 21.2 42.9%  
Shareholders   12,856 4,783 268.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   IPCA LABS  NOVARTIS  DR. DATSONS LABS  PROCTER & GAMBLE HEALTH  SANOFI INDIA  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

June WPI Inflation Data, IPO Buzz, and Top Stocks in Action Today(Pre-Open)

On Tuesday, Indian share markets fell sharply, led by weak Asian equities as worries of new lockdowns to stem surging coronavirus cases kept investors cautious worldwide.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

How to Find the Best Stocks for Day Trading - 1(Fast Profits Daily)

Jul 2, 2020

In the first of two videos, I'll show you how to identify the best stocks for intraday trading.

Two Agri Stocks Are Likely to Outperform Even in this Market(Profit Hunter)

Jul 2, 2020

Why we have recommended two agriculture stocks for our Hidden Treasure subscribers. Read on...

Smallcaps Are in a Sweet Spot Again: Are You Buying?(Profit Hunter)

Jul 3, 2020

This is why I believe smallcaps are the place to be in the near future.

How We Made 10%+ Profits Overnight(Fast Profits Daily)

Jul 3, 2020

A simple trade in natural gas delivered more than 10% overnight. Here's how we did it...

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jul 14, 2020 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA - WOCKHARDT COMPARISON

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS